Skip to main content

Table 3 Outcome parameters of MPCNL and RIRS

From: Efficacy and safety of minimally invasive percutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of upper urinary tract stones (> 1 cm): a systematic review and meta-analysis of 18 randomized controlled trials

Study

Treatments

SFR(%)

Hospitalization time(day)

Operation

Postoperative

Hb drop(g/dl)

Transfusion,n(%)

cost

Complications(%)

    

duration(min)

pain score

   

Overall n(%)

Grade I n(%)

Grade II n(%)

Grade III n(%)

Gu 2013 [25]

mPCNL

100

4.6 ± 1.8

50–135(96.2)

-

-

-

-

-

-

-

-

RIRS

89.7

1.9 ± 1.3

45–100(66.8)

-

-

-

-

- 

-

-

-

Sabnis 2013 [26]

mPCNL

97.1

2.4 ± 0.9

51.6 ± 18.5

1.9 ± 1.2

0.96 ± 0.41

 -

-

9(25.7)

8(22.9)

1(2.8)

0

RIRS

94.3

2.1 ± 0.75

47.1 ± 17.5

1.6 ± 0.8

0.56 ± 0.31

 -

-

4(11.4)

4(11.4)

0

0

Kumar 2015 [27]

mPCNL

95.1

3.1

61.1 ± 1.3

-

-

12.9

-

10(24.9)

8(20)

2(4.9)

-

RIRS

86.1

1.3

47.5 ± 1.1

-

-

0

-

4(9.4)

2(4.7)

2(4.7)

-

Lee 2015 [28]

mPCNL

85.7

1.6 ± 1.1

76.1 ± 70.6

4.2 ± 2.6

0.69 ± 0.98

-

-

15(42.9)

11(31.4)

4(11.4)

0

RIRS

97

1.5 ± 0.9

99.6 ± 60.8

5.7 ± 3.0

0.38 ± 0.97

-

-

22(62.9)

19(54.3)

3(9.1)

0

Demirbas 2016 [29]

mPCNL

80

2.46 ± 3.02

54.53 ± 23.09

4.73 ± 1.25

-

-

665

7(23.4)

2(6.7)a

5(16.7)

RIRS

74.4

1.37 ± 1.48

59.41 ± 15.78

2.30 ± 1.12

-

-

1160

6(14)

3(7)a

3(7)

Fayad 2017 [30]

mPCNL

92.72

 

71.66 ± 10.36

-

0.28

0

-

5(8.33)

5(8.33)

-

-

RIRS

84.31

 

109.66 ± 20.75

-

0.13

0

-

5(8.33)

5(8.33)

-

-

Kandemir 2017 [31]

mPCNL

93.7

54.2

59.04

-

1.06(0.1–28)

3.3

-

5(16.6)

4(13.3)

1(3.3)

0

RIRS

86.7

19

51.05

-

0.75(0.1–21)

0

-

6(19.9)

4(13.3)

2(6.6)

0

Zeng 2018 [32]

mPCNL

93.8

2.5 ± 1.1

58.6 ± 21.6

2.7 ± 1.7

1.02 ± 0.89

0

-

6(7)

9(11.7)

2(2.6)

-

RIRS

82.5

2.5 ± 1.1

52.3 ± 22.4

2.0 ± 1.5

0.43 ± 0.88

0

-

6(7)

12(14.5)

2(2.6)

-

Gucuk 2019 [33]

mPCNL

86.7

2.1 ± 2.03

98.3 ± 18.8

3.1 ± 1.4

-

3.3

-

12(40)

9(30)

3(10)

0

RIRS

83.3

1.6 ± 1.34

109.0 ± 33.8

3.0 ± 1.4

-

0

-

9(30)

6(20)

1(3.3)

2(6.6)

Jiang 2019 [17]

mPCNL

94.7

3.2 ± 0.5

54.0 ± 8.2

-

3.0 ± 2.3

-

-

4(6.9)

3(5.2)

1(1.7)

0

RIRS

92.9

3.2 ± 0.6

60.3 ± 8.5

-

2.3 ± 1.5

-

-

6(5.2)

0

4(3.4)

2(1.7)

Jin 2019 [18]

mPCNL

99.1

5.59 ± 0.82

79.6 ± 14.86

3.42 ± 1.24

1.14 ± 0.76

-

-

12(11)

0

12(11)

0

RIRS

97.3

3.15 ± 0.72

87.2 ± 13.34

1.62 ± 0.86

0.98 ± 0.68

-

-

6(5.5)

0

6(5.5)

0

Zhang 2019 [19]

mPCNL

98

5.3 ± 1.2

68.58 ± 15.82

-

0.89

1.6

4085.51 ± 416.69

10(16.7)

2(3.3)

5(8.3)

3(5)

RIRS

92

3.2 ± 0.5

93.35 ± 21.64

-

0.44

0

4657.28 ± 679.28

6(10)

2(3.3)

3(5)

1(1.7)

Yavuz 2020 [34]

mPCNL

94.1

2 (1–14)

61.6 ± 18.5

-

-

- 

632 ± 314

3(8.8)

-

3(8.8)

0

RIRS

76

1 (0.5-3)

60.7 ± 13

-

-

 -

1250 ± 505

2(6)

-

2(6)

0

Coskun 2021 [35]

mPCNL

 

4.6 ± 3,5

71.7 ± 24.4

-

-

8

-

-

7(28)

9(36)

9(36)

RIRS

 

1.2 ± 0.59

72.8 ± 24.2

-

-

0

-

-

20(78)

3(12)

0

Jain 2021 [36]

mPCNL

92.5

2.85

51.58

-

0.88

-

-

9(22.5)

2(5)

3(7.5)

4(10)

RIRS

87.5

2.45

69.75

-

0.42

-

-

16(40)

4(10)

7(17.5)

5(12.5)

Datta 2022 [20]

mPCNL

100

39.21

41.17

-

0.46

-

45.61

10(10.3)

6(6.2)

4(4.1)

0

RIRS

73

39.08

73.58

-

0.31

-

423.02

16(35)

16(35)

0

0

Liu 2022 [21]

mPCNL

86.2

3.5 ± 1.58

48.2 ± 24.25

4.6 ± 1.34

0.98 ± 0.55

5.2

-

13(22.4)

13(22.4)

-

-

RIRS

61.4

2.5 ± 1.24

43.5 ± 17.23

3.9 ± 1.07

0.76 ± 0.58

0

-

4(7)

4(7)

-

-

Sebaey 2022 [37]

mPCNL

88.6

1.41 ± 0.46

59.71 ± 19.44

 -

1.27 ± 0.1

2.9

-

3(8.6)

3(8.6)

-

-

RIRS

82.9

1.29 ± 0.44

80.43 ± 14.79

 -

1.29 ± 0.1

0

-

1(2.9)

1(2.9)

 -

-

  1. aoverall number of Grade I and Grade II; mPCNL minimally invasive percutaneous nephrolithotomy, RIRS Retrograde intrarenal surgery, Hb Hemoglobin, SFR Stone free rate
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us